How to buy Oragenics stock (OGEN)

Oragenics is a biotechnology business based in the US. Oragenics shares (OGEN) are listed on the NYSE MKT and all prices are listed in US Dollars. Its last market close was $0.38 – an increase of 0.53% over the previous week. Oragenics employs 5 staff and has a trailing 12-month revenue of around $7,466.

Our top picks for where to buy Oragenics stock

Buy Oragenics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Oragenics stock price (NYSE MKT: OGEN)

Use our graph to track the performance of OGEN stocks over time.

Oragenics shares at a glance

• Key figures

Information last updated 2024-12-25.

Latest market close	$0.38
52-week range	$0.25 - $7.74
50-day moving average more info button	$0.33
200-day moving average more info button	$0.97
Wall St. target price	$90.00
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-6.97

Is it a good time to buy Oragenics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Oragenics price performance over time

Historical closes compared with the close of $0.378 from 2024-12-24

1 week (2024-12-19)	0.53%
1 month (2024-11-26)	24.34%
3 months (2024-09-26)	-5.97%
6 months (2024-06-26)	-62.57%

1 year (2023-12-26)	-92.97%
2 years (2022-12-23)	-95.66%
3 years (2021-12-23)	28.926
5 years (2019-12-26)	32.37

Oragenics financials

Revenue TTM	$7,466
Gross profit TTM	$-9,941,163
Return on assets TTM	-219.89%
Return on equity TTM	-454.72%
Profit margin	0%
Book value	$0.51
Market Capitalization more info button	$4.8 million

TTM: trailing 12 months

Oragenics share dividends

We're not expecting Oragenics to pay a dividend over the next 12 months.

Have Oragenics's shares ever split?

Oragenics's shares were split on a 1:60 basis on 22 January 2023 . So if you had owned 60 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Oragenics shares – just the quantity. However, indirectly, the new 5900% higher share price could have impacted the market appetite for Oragenics shares which in turn could have impacted Oragenics's share price.

Oragenics share price volatility

Over the last 12 months, Oragenics's shares have ranged in value from as little as $0.2542 up to $7.74. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while Oragenics's is 0.481. This would suggest that Oragenics's shares are less volatile than average (for this exchange).

Oragenics overview

Oragenics, Inc. , a development-stage company, engages in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The company also develops NT-CoV2-1, a SARS-CoV-2 vaccine product candidate; and Lantibiotic Product Candidate, such as Mutacin 1140 (MU1140), a molecule belonging to the novel class of antibiotics. It has a license agreement with Inspirevax Inc. The company was formerly known as Oragen, Inc. Oragenics, Inc.

Frequently asked questions

What percentage of Oragenics is owned by insiders or institutions?
Currently 25.409% of Oragenics shares are held by insiders and 11.131% by institutions. How many people work for Oragenics?
Latest data suggests 5 work at Oragenics. When does the fiscal year end for Oragenics?
Oragenics's fiscal year ends in December. Where is Oragenics based?
Oragenics's address is: 4902 Eisenhower Boulevard, Tampa, FL, United States, 33634 What is Oragenics's ISIN number?
Oragenics's international securities identification number is: US6840233026 What is Oragenics's CUSIP number?
Oragenics's Committee on Uniform Securities Identification Procedures number is: 684023104